^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ACT-903

i
Other names: ACT-903, AFP + linker + maytansine
Company:
Alpha Cancer Technologies
Drug class:
Tubulin inhibitor, AFP-targeted antibody-drug conjugate
over1year
High anti-tumor activity of a novel alpha-fetoprotein-maytansinoid conjugate targeting alpha-fetoprotein receptors in colorectal cancer xenograft model. (PubMed, Cancer Cell Int)
Studies were performed to investigate the use of recombinant human AFP (ACT-101) conjugated with maytansinoid toxins for targeted toxin delivery to cancer. No obvious signs of toxicity were seen in any of the treated groups. Observed efficacy and excellent tolerability of ACT-903 in these xenograft models support advancing the development of ACT-903 toward clinical use.
Preclinical • Journal
|
AFP (Alpha-fetoprotein)
|
ACT-903